PALO ALTO, Calif., June 1, 2020 /PRNewswire/
-- Varian (NYSE: VAR) today announced two executive
appointments. Michael Hutchinson has
joined the company as Senior Vice President, Chief Legal Officer
following the previously communicated retirement plans of
John Kuo. The company also announced
that Francis (Frank) R. Facchini,
M.D., FSIR has assumed a permanent role as President of Varian's
Interventional Solutions (IS) business, effective
immediately.
Most recently, Mr. Hutchinson served as Vice President and
Advisor to the Chairman and CEO at Stryker. Prior to this role, he
served as General Counsel, Vice President and Chief Legal Officer
at Stryker, overseeing the global Legal & Compliance
organization and the corporate secretary function, and guiding the
company through more than 80 acquisitions over the span of 10
years. He began his career working for several law firms and as an
in-house attorney in the Washington,
D.C., area. He holds a law degree from George Washington University Law School and a
bachelor's degree from Clark
University.
Dr. Facchini joined Varian as Chief Medical Officer,
Interventional Solutions in 2019, and in February 2020 transitioned to interim leader of
the IS business. Since that time, he has made a significant impact
on building Varian's IS business, helping to strengthen the
portfolio for customers, solidifying a robust clinical strategy and
hiring key leaders to help the organization grow. Dr. Facchini, a
board-certified interventional radiologist, holds a clinical
appointment with VIR Chicago, an independent IR clinical practice
he co-founded. He is a member of the Society of Interventional
Radiology (SIR), where he has served as a Foundation Board Member,
and is also a member of the Society of Interventional Oncology
(SIO). He has expertise in minimally invasive, image-guided
treatment of cancer and a special interest in the research and
development of novel cancer therapies. Dr. Facchini received a
Doctor of Medicine from Loyola University, Stritch School of
Medicine, and a bachelor's degree from DePauw University.
"Varian is propelled by a bold vision for the future of cancer
care and a commitment to delivering innovative solutions for our
customers and their patients," said Dow Wilson, president and CEO.
"Both Michael and Frank are highly esteemed experts in their
disciplines, with outstanding credentials and proven track records.
We are confident that their leadership will be a tremendous asset
as we continue to work toward a world without fear of cancer."
About Varian
At Varian, we envision a world without fear of cancer. For more
than 70 years, we have developed, built and delivered innovative
cancer care technologies and solutions for our clinical partners
around the globe to help them treat millions of patients each year.
With an Intelligent Cancer Care approach, we are harnessing
advanced technologies like artificial intelligence, machine
learning and data analytics to enhance cancer treatment and expand
access to care. Our 9,200 employees across 70 countries keep the
patient and our clinical partners at the center of our thinking as
we power new victories in cancer care. Because, for cancer patients
everywhere, their fight is our fight. For more information, visit
http://www.varian.com and follow @VarianMedSys on Twitter.
Press Contact
Aimee
Corso
Health + Commerce
+1 (310) 780-2661
aimee@healthandcommerce.com
Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-appoints-michael-hutchinson-to-senior-vice-president-chief-legal-officer-and-francis-r-facchini-md-fsir-to-president-interventional-solutions-business-301068088.html
SOURCE Varian